What the source record establishes
Clinical Architecture provides terminology-management and semantic-interoperability products for mapping, normalizing, governing, and serving clinical concepts and value sets.
The maintained taxonomy connects that documented market position to Data Quality, Lineage, And Provenance. This page keeps the claim at the level supported by the source: Clinical Architecture presents an offering relevant to this work. It does not silently convert a product description into an observed result, a conformity finding, or a universal recommendation.
Current fit signal: Healthcare data and informatics teams needing enterprise terminology authoring, mapping, and distribution should evaluate Clinical Architecture.
What data quality, lineage, and provenance means in this market
Data Quality, Lineage, And Provenance should be evaluated as an operating chain rather than a feature label. The chain begins with a named business condition and governed input, passes through configured logic and accountable review, produces an output or action, handles exceptions, and preserves enough evidence for another person to reconstruct the decision later.
Semantic integrity and terminology
Risk that data move successfully but lose or distort meaning because codes, units, value sets, local terms, context, negation, status, and version provenance are incomplete or transformed incorrectly.
Boundary: A terminology map is evidence for a transformation, not an independent clinical decision or guarantee that the receiving workflow interprets the result correctly.
Data quality, completeness, and provenance
Risk that exchanged information lacks source, time, status, authorship, context, completeness, or transformation history, preventing the receiving organization from evaluating whether and how to use it.
Boundary: A source can document data availability or mapping; it does not prove clinical completeness, correctness, or use in the receiving workflow.
Activities that may sit inside the review
- code systems
- value sets
- local terminology
- mapping and normalization
- units and reference ranges
- clinical context
Who owns the decision
A capability can be technically available while operating ownership remains fragmented. The evaluation should name the person accountable for policy or business interpretation, the person responsible for configuration and data, the reviewer with authority to resolve exceptions, the approver of release or action, and the owner of monitoring and retirement.
Related domain records commonly place responsibility with clinical informatics, terminology services, data governance, analytics, interoperability engineering. The local operating model may assign those roles differently, but it should not leave them implicit.
Clinical Architecture should be asked to distinguish what the product decides, what it recommends, what it merely displays, and what remains an organizational judgment. A generic “human in the loop” statement is inadequate unless the human has time, context, evidence, and authority.
Evidence package to request from Clinical Architecture
- The exact product and package proposed, with a dated list of native, integrated, partner, service, and customer-owned components.
- A representative input set, its authoritative source, permitted use, quality checks, and version history.
- The configured workflow from intake through review, exception, approval, action, retention, and export.
- A normal result and at least two difficult exceptions, including one caused by missing or contradictory evidence.
- Role and access definitions for configuration, review, approval, override, monitoring, and administration.
- An implementation map naming integrations, migrations, customer work, provider work, services, test environments, and release gates.
- A retained decision record showing source, logic or model version, user action, timestamps, disposition, and downstream effect.
- A measurement plan with baseline, observation period, population, error threshold, exclusions, and stop condition.
Demonstration script
- Which exact Clinical Architecture product, edition, module, service, and geography support data quality, lineage, and provenance?
- What source data, content, rules, and integrations does Clinical Architecture require before the workflow can begin?
- Where does human judgment enter, and which person can approve, reject, override, or stop the data quality, lineage, and provenance workflow?
- How does the proposed configuration handle missing data, conflicting evidence, changed rules, and an expired or revoked approval?
- What record preserves inputs, transformations, user actions, exceptions, outputs, timestamps, and downstream consequences?
- Which parts are native, partner-delivered, service-delivered, or left to the customer?
- What can be exported at implementation, audit, renewal, migration, and exit?
- Which observation would falsify the current fit hypothesis for Clinical Architecture?
- Which code systems and versions are supported and licensed?
- How are local concepts mapped, reviewed, and changed?
- Are source code, normalized code, method, confidence, and history retained?
- How are units, reference ranges, status, and negation preserved?
Use the same scenario with every finalist. Let the provider explain differences in architecture, but keep the business condition, required evidence, exception, and expected decision record constant. That makes the evaluation comparable without pretending that unlike products should receive one synthetic score.
Failure modes and boundary conditions
- one universal normalized model
- clinical correctness inferred from a mapped code
- silent replacement of historical terminology
- complete record claims without a defined universe
- transport receipt treated as clinical reconciliation
- silent source overwrite
Terminology coverage, mapping method, source vocabulary licenses, update cycles, and customer adjudication vary. A normalized concept does not resolve every context, provenance, or clinical-use question.
A buyer should also distinguish absence of public evidence from evidence of absence. If Clinical Architecture has not publicly documented a required detail, the correct status is “not established in this review” until a current, attributable source or direct observation resolves it.
Authority and standards context
CARIN Blue Button 2.2.0
The 2026 release creates a current version-control question for payer and app implementations; support must be stated by version rather than as a generic Blue Button claim.
Interpretation boundary: The guide does not determine which claims a payer maintains, whether an app is trustworthy, or whether displayed information is complete.
This mapping identifies a workflow that may help organize evidence. It does not state that Clinical Architecture conforms to, complies with, or is certified against the authority.
C-CDA 5.0.0
Document exchange remains a large production reality alongside FHIR APIs. Buyers need version-aware parsing, generation, validation, provenance, and historical compatibility rather than a plan that assumes CDA has disappeared.
Interpretation boundary: C-CDA 5.0.0 publication does not automatically change current certification baselines or prove that a product correctly handles every document template.
This mapping identifies a workflow that may help organize evidence. It does not state that Clinical Architecture conforms to, complies with, or is certified against the authority.
FHIR R5 5.0.0
The newest overall release and the dominant regulatory implementation baseline are not the same thing. Buyers need an explicit version-transition plan rather than treating current FHIR as one undifferentiated feature.
Interpretation boundary: Current-published status for FHIR R5 does not mean every U.S. certification criterion, payer API, product, or implementation guide has moved from R4.
This mapping identifies a workflow that may help organize evidence. It does not state that Clinical Architecture conforms to, complies with, or is certified against the authority.
Comparable records to inspect
The following organizations also have current official positioning mapped to data quality, lineage, and provenance. Inclusion is a research pathway, not a shortlist or claim of equivalence.
- IMO Health — Terminology And Semantic-Interoperability Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
- Wolters Kluwer Health Language — Terminology And Semantic-Interoperability Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
- 1upHealth — FHIR Server, API, And Compliance Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
- Availity — Payer Interoperability And API Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
- AWS HealthLake — Cloud Health-Data Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
- b.well Connected Health — Clinical Data Network And Record-Retrieval Platform with documented positioning relevant to Data Quality, Lineage, And Provenance
Official authority sources
The following primary authority pages support the standards context used in this record. They define an evaluation boundary; they do not endorse Clinical Architecture or establish product conformity.
CARIN Blue Button 2.2.0
Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.
C-CDA 5.0.0
Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.
FHIR R5 5.0.0
Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.
Conditional conclusion
Clinical Architecture belongs in deeper evaluation for data quality, lineage, and provenance when its documented terminology and semantic-interoperability platform operating model matches the buyer's real workflow, the proposed package contains the required components, and a representative test produces reviewable evidence through normal and exception paths. The conclusion should be reversed or narrowed when the product boundary, source data, authority mapping, integration burden, human decision rights, exportability, or measured result does not meet the stated approval conditions.